Drug intelligence / Profile preview

autologous tumor antigens

Development stage: Preclinical
Lead developer: Research Genetic Cancer Centre Group
Modality: Cell Therapies
Administration: Parenteral

Overview

Autologous Tumor Antigens (ATA) is an autologous cell-derived immune therapy developed by the Research Genetic Cancer Centre Group (RGCC). The therapy utilizes cellular fragments derived from a patient's own dying tumor cells or circulating tumor cells (CTCs), including tumor proteins, membranes, organelles, RNA, and DNA. By presenting these patient-specific antigens to the immune system, ATA aims to enhance immune recognition and support the body's natural anti-tumor response. It is primarily intended for use in cancer patients to bolster immune system function against malignant cells.

Other names: Autologous Tumor Antigens (ATA)

Targets

pMHC (Peptide-MHC complex family)

Beyond the preview

Go deeper on autologous tumor antigens.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on autologous tumor antigens.

Explore the full profile